Investigating how TRAF2 and RIP1 affect breast cancer cell survival
The roles of TRAF2 and RIP1 in breast cancer cell survival
This study is looking at how certain proteins in breast cancer cells affect their survival and ability to resist treatment, with the goal of finding new ways to make treatments more effective for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11061249 on NIH RePORTER |
What this research studies
This research focuses on understanding the roles of TRAF2 and RIP1 in breast cancer, particularly how they influence cell survival and resistance to treatment. The study examines the PI3K-AKT signaling pathway, which is often altered in breast cancer, and explores how inhibiting this pathway can lead to increased cancer cell death. By using advanced biological models and assays, the research aims to identify new therapeutic targets and combinations that could improve treatment outcomes for breast cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with breast cancer, particularly those with tumors exhibiting alterations in the PI3K-AKT pathway.
Not a fit: Patients with non-breast cancer malignancies or those whose tumors do not involve the PI3K-AKT pathway may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for breast cancer, potentially reducing drug resistance and improving patient survival rates.
How similar studies have performed: Other research has shown promise in targeting the PI3K-AKT pathway in breast cancer, but this specific approach involving TRAF2 and RIP1 is relatively novel.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Habelhah, Hasem — University of Iowa
- Study coordinator: Habelhah, Hasem
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.